Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical colorectal cancer 2023-06, Vol.22 (2), p.222-230
Hauptverfasser:	Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., Aranda, E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab BRAF Clinical Trials, Phase II as Topic Colonic Neoplasms - drug therapy Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Humans Metastatic colorectal cancer Neoplastic Cells, Circulating Prognosis Prognostic factors Randomized Controlled Trials as Topic RAS Rectal Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs.
ISSN:	1533-0028 1938-0674
DOI:	10.1016/j.clcc.2023.02.004